Logo for Plus Therapeutics Inc

Plus Therapeutics Investor Relations Material

Latest events

Logo for Plus Therapeutics Inc

Q2 2024

Plus Therapeutics
Logo for Plus Therapeutics

Q2 2024

14 Aug, 2024
Logo for Plus Therapeutics

Q1 2024

15 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Plus Therapeutics Inc

Access all reports
Plus Therapeutics Inc is a clinical-stage pharmaceutical company, which develops, manufactures, and commercializes treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company was formerly known as Cytori Therapeutics Inc and changed its name to Plus Therapeutics Inc in July 2019. Plus Therapeutics Inc was founded in 1996 and is headquartered in Austin, Texas.